Consequently, CP@NP‐cRGD was shown to potently inhibit autophagy and FGFR1 pathways to overcome AZD9291 resistance in NSCLC cell lines with optimal drug protection and sequential release ability. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.